Amedisys (AMED) Tops Q1 EPS by 21c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amedisys Reports First Quarter 2019 Financial Results and Reaffirms 2019 Guidance
April 30, 2019 4:34 PM EDTBATON ROUGE, La., April 30, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2019.
Three Month Periods Ended March 31, 2019 and 2018
Net service revenue increased $68.0Â million to $467.3Â million compared to $399.3Â million in 2018.Net income attributable to Amedisys, Inc. of $31.3Â million compared to $27.2Â million in 2018.Net income attributable to Amedisys, Inc. per diluted share of $0.95 per diluted share compared to $0.79 in 2018.Adjusted Quarterly Results*
Adjusted EBITDA of $54.9Â million compared to $41.7Â million in 2018.Adjusted net service revenue of $467.8Â million compared to $399.3Â million in... More